Clinical Observation On Treatment Of Spleen - Lung Patients With Stomach - Qi Deficiency And Stable Stage By

Objective:Screen COPD patients who are deficient of lung-qi and spleen-qi in the chronic respiratory disease database, assess the efficacy of modified Buzhong Yiqi Decoction. Provide the evidence for treatment of COPD patients with deficiency of lung and spleen qi.Methods:This study was a retrospective analysis. Screened patients meet the criteria bellow:who was high-risk group COPD patient with deficiency of lung and spleen qi; who had no response to LABA/ICS or LAMA and had used Buzhong Yiqi Decoction in their treatment. We compared SGRQ score, CAT score, mMRC classification, SAS and SDS score before and after TCM treatment to assess the changes in symptoms, quality of life and psychological status.Results:There are 967 patients of stable phase COPD patient in the database in total. 682 cases had used the long-acting bronchodilator diastolic therapeutic agents (LABA+ICS and/or Lama,≥3 months).541 cases were of MMRC scores≥2.104 cases were no obvious efficacy.30 cases were the lung and spleen qi deficiency type and had used Buzhong Yiqi Decoction in their treatment. Among them, there were 18 of GOLD 3 and 12 females of GOLD 4. The mean age was 68.72+9.03 years old. The mean value of BMI was 23.46+ 4.01. SGRQ respiratory symptom scores were:45.97±17.47 before treatment,39.61±14.31 after treatment(P<0.05) in GOLD 3 group; 75.10±18.12 before treatment,65.87±17.03 after treatment(P<0.05) in GOLD 4 group. SGRQ activity scores were:44.79±18.33 before treatment,43.53±17.69 after treatment (P>0.05) in GOLD 3 group; 59.37±16.96 before treatment,56.17±18.04 after treatment (P<0.05) in GOLD 4 group. SGRQ impact scores were:37.45±19.88 before treatment,30.63±18.39 after treatment (P<0.05) in GOLD 3 group; 56.69±11.04 before treatment,49.12±11.72 after treatment (P<0.05) in GOLD 4 group。SGRQ total scores were:41.04±17.04 before treatment; 36.64±16.11after treatment (P<0.05)in GOLD 3 group; 60.41±10.46 before treatment,55.42±7.64 after treatment (P <0.05) in GOLD 4 group. CAT scores were:20.72±5.76 before treatment,19.05±4.84 after treatment (P<0.05) in GOLD 3 group; 25.42±6.83 before treatment,23.33±4.60 after treatment(P<0.05)in GOLD 4 group. mMRC scores were:2.22±0.43 before treatment,1.72 ±0.57 after treatment (P<0.05) in GOLD 3 group; 3.08±0.79 before treatment,2.25±0.75 after treatment (P<0.05) in GOLD 4 group. SAS scores were:34.50±5.22 before treatment, 34.00±5.24 after treatment(P>0.05)in GOLD 3 group; 35.00±6.76 before treatment,34.17 ±5.39 after treatment (P>0.05) in GOLD 4 group。SDS scores were:42.44±7.89 before treatment,39.89±8.04 after treatment(p<0.05) in GOLD 3 group; 40.00±9.14 before treatment,39.08±8.46 after treatment (P>0.05) in GOLD 4 group。6MWT distances were: 316.38±16.77m before treatment,330.72±18.23m after treatment(P<0.05) in GOLD 4 group; 307.62±14.38m before treatment,312.77±16.22m after treatment (P>0.05)。FEV1% were:41.00%±5.79% before treatment,41.72%±5.78% after treatmetn (P>0.05) in GOLD 3 group,24.08%±3.40% before treatment,24.58%±3.15% after treatment(P>0.05) in GOLD 4 group.Conclusion:Buzhong Yiqi Decoction in the treatment of COPD patients’with lung and spleen qi deficiency can improve their life quality and alleviate the patients depression.Due to the limited time of the study, the efficacy of Buzhong Yiqi Decoction in terms of improving functional activity, pulmonary function and anxiety is not sure.